Brenus Pharma

Brenus Pharma is a privately held, clinical-stage biotech founded in 2020 in Lyon, France. The company has developed a novel platform that creates 'ghost cell' immunotherapies designed to expose the broadest panel of cancer-associated antigens to the immune system, aiming to overcome the limitations of current immunotherapies in solid tumors. With €30M in strategic funding, Brenus is advancing its lead candidate, STC-1010, into Phase I/II trials for metastatic colorectal cancer, targeting a significant patient population with limited options. The company is led by a seasoned team with deep experience in oncology, drug development, and entrepreneurship.

Proprietary off-the-shelf platform using hapten-tagged, inactivated 'ghost cells' derived from stimulated cancer cell lines. It mimics tumor heterogeneity to present a broad panel of cancer-associated antigens, educating the immune system in vivo to recognize and attack solid tumors.

Brenus operates in the highly competitive solid tumor immunotherapy space, competing with checkpoint inhibitors, personalized cancer vaccines, oncolytic viruses, and other cell-based therapies. Its differentiation lies in its off-the-shelf, broad-antigen presentation approach designed for cold tumors like MSS-CRC.